Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Stock Analysis

Why Acusensus (ASX:ACE) Has Been Awarded a Territory-Wide Traffic Enforcement Contract by the ACT Government

Acusensus Limited (ASX:ACE) announced on 23 October 2026 that its wholly owned subsidiary, Acusensus Australia Pty Ltd, has been awarded a new master services agreement, with associated statements of work, by the AustralianCapitalTerritory. The client is the ACT Government's City and Environment Directorate. The …

Sonal Goyal | 23 October 2026

Why Adslot (ASX:ADS) Reports a Reconsolidated Group, A$1.28 Million of Cash and 1.7 Quarters of Funding

Adslot Ltd (ASX:ADS) released itsQuarterly Reportand Appendix 4C for the September 2026 quarter on 23 October 2026.SubsidiaryAdslot Technologies Pty Ltd entered voluntary administration on 18 June 2026, and a Deed of Company Arrangement (DOCA) was executed on 10 August 2026. Control of the subsidiary …

Sonal Goyal | 23 October 2026

Why Arovella Therapeutics (ASX:ALA) Expects First Patient Dosing in Its CAR-iNKT Lymphoma Trial in October 2026

Arovella Therapeutics Limited (ASX:ALA) said in its quarterly update for the period ended 30 September 2026 that its focus is ALA-101, a CD19-targeted CAR-iNKT cell therapy for blood cancers. The company said two manufacturing batches were manufactured and released for clinical use in September …

Sonal Goyal | 23 October 2026

Why Alkane Resources (ASX:ALK) Reported 40,740 Ounces of Gold-Equivalent Output and Reaffirmed FY27 Guidance

Alkane Resources Limited (ASX:ALK) reported gold-equivalent production of 40,740 ounces for the September 2026 quarter, comprising 39,823 ounces of gold and 396 tonnes of antimony.All-In Sustaining Cost(AISC) was A$2,805 per gold-equivalent ounce, which the company said is below its FY27 guidance range, and cash …

Sonal Goyal | 23 October 2026

Why Alma Metals (ASX:ALM) Reported a 386.6 Metre Copper Intercept at the Briggs Project in Queensland

Alma Metals Limited (ASX:ALM) reported assays on 23 October 2026 for four infill holes, 26BRD0043 to 26BRD0046, drilled in the south-eastern part of the Briggs Mineral Resource Estimate (MRE) in Queensland. Hole 26BRD0046 returned 386.6 metres at 0.20 per cent copper from 43 metres, …

Sonal Goyal | 23 October 2026

Why Anagenics (ASX:AN1) Reports a $10,000 Net Operating Cash Outflow After Restructuring

Anagenics Limited (ASX:AN1) reported a net operating cash outflow of $10,000 for the September 2026 quarter, compared with about $0.3 million in the first quarter of FY2026. The figures are in its Appendix 4C and activity report for the first quarter of FY2027, released …

Sonal Goyal | 23 October 2026

Why Aldoro Resources (ASX:ARN) Has Appointed a Strategic Adviser for Its Kameelburg Project in Namibia

Aldoro Resources Limited (ASX:ARN) has formalised a strategic developmentPartnershipfor its Kameelburg Project in Namibia, appointing Shenghuang Weiye Investment Management Consulting Centre, referred to in the announcement as Shenhuang, as Strategic Development Adviser. The appointment covers the next phase of the project's development and commercialisation. …

Sonal Goyal | 23 October 2026

Why Arafura Rare Earths (ASX:ARU) Has Named Ian Murray as Chair as Nolans Rare Earths Construction Begins

Arafura Rare Earths Limited (ASX:ARU) has appointed Ian Murray as chair, effective at the conclusion of its annual general meeting on 22 October 2026, while the company said early construction activity has begun at its Nolans rare earths project in the Northern Territory.

Sonal Goyal | 23 October 2026

Why Australian Silica Quartz Group (ASX:ASQ) Is Seeking a Kaolin Offtake Partner for Its White Swan Project

Australian Silica Quartz Group Ltd (ASX:ASQ) has set out its plan to secure an offtake partner for its White Swan kaolin project near Esperance in Western Australia, in its quarterly activities andCash Flowreport for the quarter ended 30 September 2026. The company says finding …

Sonal Goyal | 23 October 2026

Why Amplia Therapeutics (ASX:ATX) Has Received a A$4.78 Million R&D Tax Incentive Rebate for Its Pancreatic Cancer Programme

Amplia Therapeutics Limited (ASX:ATX) has received A$4,778,235.52 from the Australian Taxation Office under theResearch and DevelopmentTax Incentive, covering the financial year ended 31 March 2026. The company announced the receipt on 22 October 2026.

Sonal Goyal | 23 October 2026
Support

Hi! How can we help you today?

Loading…